Regencell Bioscience (RGC) has had the highest return since January 1, 2025 by a US stock with a market cap of $2,015+, returning 12,609.6%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 12,609.58% |
Amark Preci (AMRK) | 12,374.13% |
QMMM Holdings Limited Ordinary Shares (QMMM) | 9,155.81% |
Abivax SA American Depositary Shares (ABVX) | 1,489.09% |
Diginex Limited Ordinary Shares (DGNX) | 1,389.2% |
FiEE (FIEE) | 1,014.68% |
Zepp Health (ZEPP) | 960.38% |
Oncology Institute (TOI) | 939.22% |
Abits (ABTS) | 832.6% |
DeFi Development (DFDV) | 819.9% |
Palvella Therapeutics (PVLA) | 769.16% |
Newegg Commerce (NEGG) | 758.88% |
Cidara Therapeutics (CDTX) | 711.77% |
Relmada Therapeutics (RLMD) | 703.78% |
Celcuity LLC (CELC) | 686.99% |
Lizhi (SOGP) | 653.99% |
Anbio Biotechnology Class A Ordinary Shares (NNNN) | 634.22% |
Terns Pharmaceuticals (TERN) | 613.3% |
TMC the metals (TMC) | 584.21% |
Nanobiotix (NBTX) | 576.21% |
Sandisk (SNDK) | 543.1% |
Avino Silver & Gold Mines (ASM) | 513.19% |
Inhibrx Biosciences (INBX) | 510.78% |
Rich Sparkle Holdings Limited Ordinary Shares (ANPA) | 500% |
ThredUp (TDUP) | 489.58% |
